CSTL logo

Castle Biosciences (CSTL)

Profile

Full Name

Castle Biosciences, Inc.

Ticker Symbol

CSTL

Exchange

NASDAQ

Country

United States

IPO

July 25, 2019

Indexes

Not included

Employees

761

Key Details

Price

$21.05(+5.83%)

Market cap

$607.19M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$332.07M(+51.09% YoY)

Annual EPS

$0.62(+128.97% YoY)

PE ratio

33.95

Next earnings date

May 2, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Feb 28, 25 Baird
Outperform
Jan 2, 25 Stephens & Co.
Overweight
Nov 6, 24 Scotiabank
Sector Outperform
Nov 5, 24 Lake Street
Buy
Nov 5, 24 Keybanc
Overweight
Nov 5, 24 Baird
Outperform
Oct 29, 24 Canaccord Genuity
Buy
Oct 14, 24 BTIG
Buy
Aug 6, 24 Stephens & Co.
Overweight
Aug 6, 24 Baird
Outperform

Institutional Ownership

  • What is the ticker symbol for Castle Biosciences?
  • Does Castle Biosciences pay dividends?
  • What sector is Castle Biosciences in?
  • What industry is Castle Biosciences in?
  • What country is Castle Biosciences based in?
  • When did Castle Biosciences go public?
  • Is Castle Biosciences in the S&P 500?
  • Is Castle Biosciences in the NASDAQ 100?
  • Is Castle Biosciences in the Dow Jones?
  • When was Castle Biosciences's last earnings report?
  • When does Castle Biosciences report earnings?
  • Should I buy Castle Biosciences stock now?

What is the ticker symbol for Castle Biosciences?

The ticker symbol for Castle Biosciences is NASDAQ:CSTL

Does Castle Biosciences pay dividends?

No, Castle Biosciences does not pay dividends

What sector is Castle Biosciences in?

Castle Biosciences is in the Healthcare sector

What industry is Castle Biosciences in?

Castle Biosciences is in the Diagnostics & Research industry

What country is Castle Biosciences based in?

Castle Biosciences is headquartered in United States

When did Castle Biosciences go public?

Castle Biosciences's initial public offering (IPO) was on July 25, 2019

Is Castle Biosciences in the S&P 500?

No, Castle Biosciences is not included in the S&P 500 index

Is Castle Biosciences in the NASDAQ 100?

No, Castle Biosciences is not included in the NASDAQ 100 index

Is Castle Biosciences in the Dow Jones?

No, Castle Biosciences is not included in the Dow Jones index

When was Castle Biosciences's last earnings report?

Castle Biosciences's most recent earnings report was on Feb 27, 2025

When does Castle Biosciences report earnings?

The next expected earnings date for Castle Biosciences is May 2, 2025

Should I buy Castle Biosciences stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page